Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Innovations in Clinical Neuroscience|February 6, 2026
Neurocognitive Disorders: Systematic Review of Approved (2008-2024) and Pipeline Phase III MedicationsJayant Totlani, Muhammad Arsalan Bashir, Laurel Tay, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral DeficitsGwendalyn D King, Kurt M Kroeger, Catherine J Bresee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 20, 2008
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficitsGwendalyn D King, Kurt M Kroeger, Catherine J Bresee, et al.
Journal of Clinical Psychopharmacology|August 14, 2025
Sleep-wake Disorders: Systematic Review of Approved Psychiatric Medications (2008 to 2024) and Pipeline Phase-3 MedicationsLauren Dugan, Aasim Naqvi, Ashley Ngor, et al.
Neuroscience Applied|July 14, 2025
Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008-2024)Salma Abdelmoteleb, Jayant Totlani, Salma Ramadan, et al.
Drugs in Context|April 14, 2025
Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008-2024) and pipeline phase III medicationsEmile Tadros, Shirley Keerthana, Samar Padder, et al.
International Journal of Psychiatry in Medicine|December 20, 2024
Systematic review of long-acting injectable antipsychotic medications approved from 2008 to october 2024 and agents in phase 3Ashley Meyer, Kyla Truman, Jayant Totlani, et al.
BMC Psychiatry|October 7, 2025
Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medicationsWaguih William IsHak, Drew Hirsch, Sabrina Renteria, et al.
Human Gene Therapy Methods|September 7, 2012
Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialA K M Ghulam Muhammad, Weidong Xiong, Mariana Puntel, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 28, 2010
Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathologyDaniel Larocque, Nicholas S R Sanderson, Josée Bergeron, et al.
Pageof 4